Navigation Links
Geriatrician Care Guards Against Risk of Inappropriate Meds
Date:1/25/2008

and comprehensive medicine review."

More information

To learn more, visit the American Geriatrics Society.



SOURCES: Mary Jo V. Pugh, Ph.D., R.N., research health scientist, South Texas Veterans Health Care System, and assistant professor, University of Texas Health Science Center at San Antonio; Dr. James S. Goodwin, professor, geriatrics, and director, Sealy Center on Aging at the University of Texas Medical Branch at Galveston; February 2008, Medical Care


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

1

GOOD

Page: 1 2 3

Related medicine news :

1. TriWest Contributes $75,000 to Agencies Supporting California Guardsmen
2. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
3. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
4. Despite overeating, morbidly obese mice gain protection against diabetes
5. Alvarado Hospital Files Countersuit Against Blue Shield
6. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
7. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
8. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
9. $52.5 Million Settlement Against Sepracor Inc. Approved
10. The fight against colorectal cancer
11. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Geriatrician Care Guards Against Risk of Inappropriate Meds 
Geriatrician Care Guards Against Risk of Inappropriate Meds
Breaking Medicine News(10 mins):Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2Health News:Possible ovarian cancer treatment target identified 2Health News:Testosterone Gets Bad Rap: Study 2Health News:Testosterone Gets Bad Rap: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 1Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 2Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 3Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 4Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 1Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 2Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 3Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 1Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 2Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 3Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 4
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 2Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 3